AstraZeneca and Bristol-Myers Squibb Discuss Potential Merger Valued at $400 Billion
AstraZeneca and Bristol-Myers Squibb have held talks over the past several months about a potential merger, with the combined company valued at roughly $400 billion, though it remains unclear whether a deal will be reached. Neither company immediately responded to requests for comment. As of last Friday, AstraZeneca had a market capitalisation of £196 billion (about HK$2.07 trillion), while Bristol-Myers Squibb stood at $133 billion (about HK$1.04 trillion). Bristol-Myers Squibb, one of the world’s ten largest drugmakers, has become a major cancer-treatment player through seven acquisitions since October 2007.
- Effective
- 0
- Intensity
- 60
- Confidence
- 40%
- Horizon
- Medium term